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The recent sequencing of the human genome, resulting from two independent 
global efforts, is poised to revolutionize all aspects of human health.  This 
landmark achievement has also vindicated two different methodologies that 
can now be used to target other important large genomes.  The human 
genome sequence has revealed several novel/surprising features notably the 
probable presence of a mere  30-35,000 genes. In depth comparisons have led 
to classification of protein families and identification of several orthologues 
and paralogues.  Information regarding non-protein coding genes as well as 
regulatory regions has thrown up several new areas of research.  Although 
still incomplete, the sequence is poised to become a boon to pharmaceutical 
companies with the promise of delivering several new drug targets.  Several 
ethical concerns have also been raised and need to be addressed in earnest.  
This review discusses all these aspects and dwells on the possible impact of 
the human genome sequence on human health, medicine and also health care 
delivery system. 
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Man’s unending quest for knowledge and to explore and unfold the mysteries of 
nature has resulted in several important discoveries that have formed the basis for several 
remarkable achievements.  Scientists have now undertaken yet another path breaking 
endeavour to define the innermost reaches of the human cell; to unravel the complete 
information encoded by the human genome, under the umbrella of the Human Genome 
Project.  A private funded effort led by Craig Venter of Celera Genomics has 
simultaneously been able to decode the human genome sequence.  These efforts have 
now given birth to new endeavours to understand what this sequence means in terms of 
human health, disease and development.  The project has also facilitated rapid advances 
in the field of engineering and informatics.  The availability of the human genome 
sequence will have a tremendous impact on biomedical sciences and the way medicine is 
practiced.  We can now start asking questions pertaining to human health and disease, 
how variations in the genome result in disease.  The human genome sequence will have 
(and is already having) a tremendous impact on understanding genetic disorders.  The 
unraveling of genetic loci/genes responsible for important genetic disorders in the pre-
genomic era was very slow.  Out of the more than 6000 recorded inherited disorders only 
75 were traced back to their genes using positional cloning and other approaches.  The 
physical map of the human genome has assisted directly in identifying about 100 more 
disease causing genes and continuing efforts will possibly identify more disease related 
loci.  Most inherited diseases are rare, but taken together, the more than 6,000 disorders 
known to result from single altered genes rob millions of healthy and productive lives.  
Today, little can be done to treat, let alone cure, most of these diseases.  But identifying a 
gene allows scientists to study its structure and characterize the molecula r alterations, or 
mutations, that result in disease.  The complete sequencing of the human genome will 
not only fasten the pace of gene discovery in unigene disorders, but more importantly 
will help in understanding the molecular basis for multigene disorders.  Progress in 
understanding the causes of cancer, for example, has taken a leap forward by the recent 
discovery of cancer genes.  The unraveling of the human genome sequence, has also 
thrown up several ethical issues since the genome sequence available  in databases is 
actually derived from a group of individuals, and several investigators and thinkers have 
raised the “ethics” of this ‘private’ information becoming ‘public’. 
The history 
The foundation of this massive human genome sequencing endeavour could be 
considered to be laid way back in the early part of the 20th century, with the rediscovery 
of the Mendelian laws (Fig. 1), which has spurred the numerous advances we have made 
in the field of genetics.  All the developments that have laid the foundation for the 
herculean human genome sequencing effort, are summarized in Fig. 1. 
The idea of sequencing the entire human genome was first mooted by the US 
Department of Energy (DOE) at scientific meetings organized from 1984-86. A US 
National Research Council committee formally endorsed the project in 1988 in a broader 
sense by including sequencing of model organisms like bacteria, yeast, worms, flies etc.  
The project was launched in the US as collaboration between the DOE and the National 
Institutes of Health (NIH). The Office of Genome Research was established in the NIH 
in 1987, which later came to be known as the National Center for Human Genome 
Research (NCHGR).  By late 1990, countries such as England, France, Japan and the 
European community also joined the effort.  In 1997, it was renamed as the National 
Human Genome Research Institute (NHGRI), under the leadership of 
Dr Francis Collins.  In 1998, the public funded group, established five high speed 
sequencing centers viz., the Sanger Center, UK; the US Department of Energy Joint 
Genome Institute in Walnut Creek, California, USA; Washington University School of 
Medicine in St. Louis, USA; the Whitehead Institute for Biomedical Research in 
Cambridge, Massachusetts, USA; and Baylor College of Medicine in Houston, Texas, 
USA.  In 1999, the idea of producing a working draft sequence was mooted and 
approved in order to satisfy the hunger of several thousand scientists worldwide for 
human genome sequence information.  This ‘working’ draft sequence was released in 
June 2001. It is expected that the final sequence would be released some time during 
2003. 
The human genome sequence has been unraveled by two more or less independent 
efforts.  One, the public funded Human Genome Project (to be referred henceforth as 
HGP), and the other the private funded effort of Celera Genomics.  Begun in 1990, the 
HGP was a 12 yr effort coordinated by the Department of Energy, USA, and the National 
Institutes of Health, USA under the overall leadership of J D Watson, the Nobel laureate 
credited with the co-discovery of the structure of DNA.  The project was originally 
planned to last 15 yr, but effective resource management and technological advances 
accelerated the completion date to 2001.  Several important technological developments 
have activated the genome sequencing efforts.  These include developments in the field 
of DNA sequencing and perhaps more importantly in the field of software development.  
The DNA sequencing developments include (i) four colour fluorescence based sequence 
detection1; (ii) dye-labeled terminators2; (iii) better fluorescent dyes with improved 
incorporation frequencies3; (iv) efficient polymerase enzymes suited for cycle 
sequencing4; and (v) capillary gel electrophoresis5.  Simultaneous developments in the 
field of automation and robotics helped in speeding up the process of sample preparation 
for sequencing.   
 
 
 
  
Fig. 1. A time-line showing important discoveries that have laid the 
foundation for the Human Genome Project.  The figure also indicates important 
milestones in the path to the generation of complete nucleotide sequence of the 
human genome.  
Some of the important improvements in the computing arena included the PHRED 
software package for assigning a ‘base-quality score’ in fluorescence based 
sequencing6,7. The PHRAP software was developed to assemble the sequence data 
generated by using PHRED.  Several softwares were also developed for arranging the 
final sequence data.  The amount of sequence deposited in Genbank saw a quantum leap 
because of the development of these technologies (Fig. 2).  These developments also 
spurred several genome sequencing initiatives and over the years, the total number of 
finished genomes has shown a tremendous increase, with a phenomenal increase being 
seen since 1999 (Fig. 3). 
The project goals identified in the beginning by the HGP included: (i) determine the 
sequences of the 3 billion chemical base pairs that make up human DNA; (ii) identify all 
the approximately 100-15,000 estimated genes in human DNA; (iii) store this 
information in databases; (iv) improve tools for data analysis; (v) transfer related 
technologies to the private sector; and (vi) address the ethical, legal, and social issues 
(ELSI) that may arise from the project. 
  
Fig. 2. The pace of deposition of DNA sequences in Genbank.  The figure also highlights important 
technological and other developments that correlate with increase in the amount of sequence deposited. 
 
 
Fig. 3. A time line showing the total number of completed genome sequencing efforts.  The histogram 
includes the genomes of all eukaryotic and prokaryotic organisms, that were completed by the end of 2002.  
Each bar indicates the total number (which includes the total for previous years).  The total number of viral, 
chloroplast and mitochondrial genome sequences completed till 2002 are shown separately. 
 Although the private funded effort originated in 1991 at the National Institutes of 
Health, it got separated from the HGP under the leadership of Craig Venter, through the 
formation of The Institute of Genome Research (TIGR) and later the Celera Genomics. 
This review highlights the background which led to this enormous global effort followed 
by a description of the distinct methodologies followed by the two groups, before 
describing the salient features of the human genome. 
Two distinct approaches 
The public funded human genome project arose from two key insights during the mid 
1980s, viz., (i) that the availability of information on the whole genome sequence would 
greatly accelerate biomedical research; and (ii) that such an effort required a huge 
amount of infrastructure building.  
A programme was launched by Botstein and colleagues8 to create a human genetic 
map to locate disease genes based solely on their patterns of inheritance. The sequence of 
the lambda and phiXl74 bacteriophages9 provided the initial confidence booster for 
undertaking this project.  A little later in mid 80s work was initiated to create physical 
maps of genomes of the yeast, Saccharomyces cerevisiae10 and the worm Caenorhabditis 
elegans11. Identification of new genes received a shot in the arm by the discovery of the 
revolutionary technique of expressed sequence tags (ESTs) that involved random 
shotgun sequencing of cDNA fragments for high throughput gene discovery12. The EST 
method is the principal method of gene discovery used by scientists around the world 
and has contributed to the discovery of many disease genes including the colon cancer 
genes13,14. ESTs comprise almost 70 per cent of all Genbank accessions. 
The human genome project followed the hierarchical shotgun method, illustrated in 
Fig. 4. The complete sequencing of genomes of model organisms including yeast15 and 
C. elegans16 genomes provided evidence that large scale genome sequencing was indeed 
possible and also validated the two-phase hierarchical paradigm of genome sequencing.  
In the first step, the genome is divided into appropriately sized fragments and each 
fragment is sequenced to a high degree of redundancy (by sequencing randomly selected 
sub fragments).  The second step is the finishing phase, in which the final sequence is 
generated by compiling the sequence data from each fragment, the so-called ‘gaps’ are 
closed and ambiguities are resolved.  The development of bacterial artificial 
chromosomes (BACs) was another shot in the arm for the HGP as it became feasible to 
stably maintain large chunks of human DNA in Escherichia coli17. Under this scheme, a 
large set of BAC clones covering the entire genome is generated and independent 
shotgun sequencing is carried out on each of these clones.  Previously constructed 
genetic and physical maps were used to choose the BAC clones for sequencing specific 
known regions.  Later each BAC clone was restricted with HindIII and the DNA band 
pattern for each clone was recorded thus assigning a specific fingerprint to each clone.  
Then each BAC clone was positioned on the chromosome by anchoring them with the 
previously determined genetic and phys ical maps.  Techniques such as fluorescent in situ 
hybridization (FISH) and probe hybridization were used for this purpose.  New sequence 
tagged sites (STS) markers were also generated for chromosomal position where 
previous markers were unavailable.  An STS is defined by two short synthetic sequences 
(typically 20-25 base pairs) designed from a region of sequence that appears as a single 
copy in the human genome.  Clones with minimum overlap were used to reduce 
redundancy.  However, these overlaps, wherever present, proved to be a rich source for 
the identification of single nucleotide polymorphisms (SNPs).  In fact more than 1.4 
million SNPs were generated based on overlapping clones alone18. Although each 
collaborating center used a different strategy for sequencing, since all of them used the 
two common softwares (PHRED and PHRAP), there was no difficulty in combining the 
data., The overall sequence coverage was about 4.5 fold for the draft sequence output, 
i.e., each base was sequenced 4-5 times.  The finished human genome sequence stood at 
835 Mb in October, 2000, which is more than 25 per cent of the total human genome 
sequence.  The draft sequence released in February, 2001, included 2,212,974 kilo bases 
of accurate completed sequence, which covered about 63 per cent of the complete 
genome.  As on January 5, 2003, about 98 per cent of the genome has been completed.  
This effort has provided an estimate of the total human genome size to be approximately 
3.3 Gb. The approximate size of each chromosome has also been determined e.g., 
chromosome 1 - 220 Mb, chromosome 21-35 Mb, X chromosome - 130 Mb, Y 
chromosome - 20 Mb etc. 
The private human genome sequencing effort under the leadership of Craig Venter 
was initiated in NIH.  He first showed in 1991 how the revolutionary EST method could 
be used to quickly (and cheaply) identify genes in the human genome. Adams et al12 
ligated the EST approach to automated sequencing.  This sparked the beginning of the 
controversy between Venter and the HGP.  The large scale EST generation resulted in 
development of new algorithms at The Institute for Genomics Research (TIGR) in 1993 
to analyze the large volumes of cDNA sequence data19,20.  In 1997, Venter’s lab tested 
the revolutionary four fluorescent dye technology for DNA sequencing, resulting in 
automated DNA sequencing.  The whole genome shotgun approach for sequencing the 
human genome was initially ridiculed by most experts.  The feasibility of the shotgun 
approach was validated when the 49 kb bacteriophage genome was sequenced in 19829. 
In May 1998, Celera Genomics was formed with a stated mission to sequence the 
entire human genome using a breakthrough DNA analysis technology developed by 
Applied Biosystems and the TIGR whole genome shotgun method.  As a prelude to the 
human genome, Celera announced it would sequence the fruit fly genome.  A formal 
collaboration was established between Celera and the Berkeley Drosophila Genome 
Project with the goal of publishing a highly accurate, contiguous genome sequence.  A 
new and advanced assembly algorithm developed by Eugene Myers of Celera was used 
to assemble the sequence.  The 120 Mb euchromatic region of the Drosophila genome 
was sequenced within 1 yr and published in March 200021-23. This effort revealed that a 5 
fold coverage of the genome was enough to yield an authentic output rather than the 
previously believed 10 fold.  Armed with this observation and taking advantage of the 
sequence data being deposited in the Genbank by the public HGP, Venter’s group began 
their human genome sequencing effort on September 8, 1999 and completed the 
sequencing on June 17, 2000.  The assembly was completed in October 2000. 
During the initial stage of sample collection, several concrete steps were taken by the 
Venter’s group to ensure that recommendations of the Helsinki Declaration, for 
conducting experiments on human subjects, were properly followed.  The privacy and 
confidentiality of the donors was ensured through a two step consent process and a 
random sample coding system.  Given the vast ethnic diversity of Homo sapiens, care 
was taken to ensure that each donor belonged to different ethnic backgrounds including 
African-American, Chinese, Hispanic, Caucasian etc.  A total of 21 donors was initially 
screened.  For the final sequencing reactions, only five subjects were used; three females 
and two males.  These included one African-American, one Asian-Chinese, one 
Hispanic- Mexican, and two Caucasians. 
The first important requirement for the whole genome shotgun sequencing is a 
genomic library of a very high quality which must include the following aspects: (i) the 
library must have equal representation of all parts of the genome; (ii) it should be devoid 
of contaminating DNA from other species, like Esch. coli; (iii) a very high percentage of 
clones should actually have an insert; and (iv) separate libraries should be made for 
specific DNA sizes.  The Venter’s group constructed three libraries, each having insert 
size in the range of 2 kb, 10 kb, and 50 kb respectively.  The sequence obtained from 
opposite ends of a particular clone were referred to as ‘mate pairs’.  Knowing that two 
sequences are derived from the same clone allows these sequences to be linked, even if 
the full insert of the clone is unavailable.  This is the key to the sequencing strategy 
called whole genome shotgun (WGS) assembly24. Each sequencing reaction was checked 
for homology with contaminants such as Esch. coli, human mitochondrial DNA or the 
plasmid vector sequences (used for library construction).  Only highly accurate 
sequencing reactions were selected for further analysis. 
 
Fig. 4. A depiction of the whole-genome assembly strategy.  A contig and the consensus sequence are first 
created by combining data from overlapping shredded bactig fragments, derived from data deposited in 
Genbank by the human genome project (HGP), (plain lines) and internally derived sequence reads from five 
different individuals (solid lines).  The consensus represents contigous regions in the human genome, so the 
term contig.  Contigs are combined to produce scaffolds by using mate pair information.  The mate pairs 
help in providing a reasonably accurate measure of the gap between two contigs.  Scaffolds are then mapped 
to the genome with sequence tagged sites (STS) physical map information. 
For assembling the final sequence, two sets of data were used.  One was generated by 
the strategy outlined in Fig. 4 using the DNA isolated from the donors.  The other data 
were derived from the sequence generated by the public sequencing effort from the 
Genbank database.  The latter was filtered by removing the contaminating sequences and 
the synthetic sequence was shredded to generate shotgun data, similar to the ones 
generated by the sequencing efforts of Celera themselves and then assembled to generate 
the final sequence.  The final sequence thus generated from the synthetic sequence was 
then compared with the sequence generated in Celera.  This approach has been termed 
the ‘whole genome assembly approach’.  In another approach, the data from Celera and 
the HGP were independently partitioned into sets that represented large chromosomal 
segments, and then shotgun assembly was performed on each set.  The success of 
Venter’s efforts has validated the utility of the whole genome shotgun sequencing for 
large genomes.  While the smaller bacterial genomes can be tackled by direct 
sequencing, larger ones like that of drosophila or humans require the use of genetic 
markers.  The whole genome assembly approach is cheaper than the BAC-based 
approach.  However, the BAC-based approach is more efficient for resolving sequencing 
anamolies and for determining the sequence of regions that are refractory to DNA 
sequencing, such as regions high in G+C content. Celera has now turned to the 
sequencing of the mouse genome, which is of critical importance to biomedical 
researchers as a model for studies of human biology and medicine. 
Important features of the human genome sequence  
The coding region of any genome can be divided into two classes viz., protein coding 
regions and non-protein coding regions.  The latter consists of rRNAs; small nucleolar 
RNAs required for rRNA processing; small nuclear RNAs (components of SNRPS) 
required for splicing; and tRNAs.  There are other species of non-coding RNAs 
including the telomerase RNA, the signal recognition particle RNA molecules and RNA 
molecules of novel/unknown function e.g., the Xist RNA implicated in X chromosome 
inactivation.  Computational prediction of such RNA molecules is difficult since it 
cannot be done based on cDNA information nor by gene-finding algorithms which are 
based on ORF prediction.  A total of 497 tRNA genes have been estimated in the draft 
genome sequence18. In addition, about 324 pseudogenes were also discovered.  The total 
tRNA genes in humans is less than that of the worm but more than that of the fly.  The 
number of tRNA genes does not depend on the complexity of the organism but on the 
demand for tRNAs in certain tissues or stages of development like in the case of silk 
worm.  The tRNA genes are clustered in specific regions, e.g., almost a whole set of 
genes is concentrated in a 4 Mb region in chromosome 618. The genes for the large 
submit and small subunit rRNAs are present as a 44 kb tandem repeat in multiple copies 
in the short arm of chromosomes 13, 14, 15, 21, and 2218. 
Perhaps the most challenging and definitely the most important task after completion 
of the draft genome sequence was gene identification, with the ultimate goal of 
completing the ‘periodic table’ of life, which will include the complete list of genes and 
their function.  The sequencing of the human genome has now given birth to several new 
disciplines in the field of genomics viz. 
(i) Functional genomics: Experimental assignment of biological functions to genes; 
(ii) Structural genomics: Elucidation of 3-D structure of gene products, and prediction of 
protein functions; (iii) Proteomics: Studying protein complement of a cell in a specific 
state/time; (iv) Pharmacogenomics: Designing custom drugs; (v) Comparative genomics: 
Studying evolution at the molecular level; (vi) Molecular epidemiology: Molecular 
typing of strains of infectious agents, based on the genome sequence. 
It is amazing how human cells can scan through millions of base pairs to accurately 
detect sequences to be transcribed and also carry out post transcriptional processing as 
desired.  It was a challenge for the two sequencing efforts to accurately predict gene 
structure in the human genome, to the extent possible.  Gene prediction in bacterial 
genomes is comparatively easier since direct identification of ORFs in smaller genomes 
is possible.  However, prediction in larger eukaryotic genomes is very difficult due to a 
lower signal-to-noise ratio.  This is especially true for the human genome that has a 
smaller coding area than the worm and the fly genomes. The problem is magnified 
several fold for the human genome since human genes tend to have very small exons 
interrupted by large introns.  Computer programs for gene prediction are based on 
available cDNA sequences and/or presence of similar known genes from other 
organisms.  Gene prediction is based on a combination of three simple approaches viz., 
experimental evidence from ESTs and/or cDNA sequences, indirect evidence from 
previously identified genes from human or other organisms and computational 
approaches based on information about splice sites, codon bias etc.  Previous estimates 
based on reassociation kinetics had put the gene number around 40,000. Walter Gilbert 
suggested in the mid 80s that the number should be about 1,00,000 based on the ratio of 
a typical gene to the total size of the genome.  Another estimate of 
70-80,000 was made based on the density of CpG islands.  However, it was later felt that 
the brain alone would have about 1,00,000 specific transcripts.  With the advent of the 
EST technology, and based on information regarding CpG islands and transcript 
densities, Incyte Inc. provided an estimate of 142,634 total human genes.  Three recent 
estimates of gene number are (i) 35,000 based on EST data in conjunction with 
chromosome 22 data; (ii) 28-35000 based on sequence conservation between human and 
the puffer fish Tetraodon nigroviridis genomes and; (iii) 35000 based essentially on data 
from chromosome 21, 22. 
Gene prediction was initiated by the IHGSC based on computational approaches using 
the Genescan software and then each prediction was confirmed based on EST data and 
homology with other known genes18. In a complementary approach, they first used the 
EST data that was then extended to use the computational approach.  Comparison of 
results obtained by using these two methods as well as information available on 
previously determined genes resulted in a considerable amount of overlap.  From this 
compilation, a non-redundant set was created which has been termed as the Initial Gene 
Index (IGI), that includes only about 21,000 true genes18. The gene prediction estimate 
was confirmed by comparing with (i) the predicted genes for the mouse; (ii) the 
completely sequenced human chromosomes 21 and 22 and; (iii) the ‘new genes’ 
identified by independent studies.  This resulted in an approximate estimate of the total 
number of genes to be about 32,000.  The total gene estimate is about 25,000 for the 
plant belonging to the mustard family, Arabidopsis thaliana, 19-20,000 for the worm, for 
Drosophila it is about 13-14,000 and for the yeast it is about 6000. Humans thus have 
only double the amount of genes in the worm or the fly.  However, the genes in the 
human genome are spread over a much larger area than the worm or the fly18. 
The Celera group has developed a program called ‘Otto’ for gene prediction25. This 
program takes into consideration the homology with existing protein sequences (mainly 
from mouse), and similarity with ESTs or other mRNA data.  This software was 
developed by keeping in mind how a human curator will actually carry out the job of 
genome annotation.  Venter and coworkers have predicted about 30,000 genes, resulting 
from annotation of 95 per cent of the euchromatic region25. This is similar to the number 
predicted by the other group.  However, detailed annotation, comparison with other 
mammalian genomes such as the mouse (Mus musculus) and experimental approaches 
would be required to be carried out in the near future to determine the exact number. 
How do we explain the small gene number?  Haldane had predicted way back in 1937 
that having too large a number of genes would be deleterious to organisms, since more 
targets would be available that could be inactivated through mutations, thereby resulting 
in zygote mortality.  Based on estimates of mutation rates, Muller in 1967 estimated the 
number of human genes to be about 30,00025.  Several features of the human genome aid 
in a greater proteome complexity arising out of a moderate increase in gene number.  
These include the phenomenon of alternate splicing, RNA editing, internal ribosome 
entry sites, alterations in nature of protein-protein interactions, protein modifications and 
localization, etc.  It is predicted that alternative splic ing, where the primary transcription 
product of one gene is spliced in different ways to generate more than one kind of 
mRNA molecules which then are translated into different protein products, alone will 
result in almost a five-fold increase in primary protein products. 
Alignment of the sequence of known genes with the draft sequence has provided 
useful information regarding exon-intron boundaries, which is important for designing 
PCR based diagnostics for molecular genetic disorders18. It also helps to map genes in 
relation to neighboring markers.  There is a lot of variation in intron/exon size and gene 
size in the human genome.  Some human genes are very big like the dystrophin gene, 
which is 2.4 Mb long, and the titin gene, which has 178 exons.  The average size of the 
coding sequence of a human gene is 1340 bp and most exons fall within 50-200 bp18. An 
analysis of smaller exons (less than 19 bp) has revealed a purine bias that might facilitate 
the splicing process.  The average size of introns are more or less conserved in the 
human, worm and the fly genomes18. GC-rich regions in the human genome are usually 
gene rich with shorter exons whereas AT-rich regions are gene poor with genes having 
large introns.  Conserved splice site sequences were studied by aligning the draft 
sequence with the known EST sequences18. As many as 98 per cent of the genes use the 
conserved GT dinucleotide at the 5’ splice site and the AG dinucleotide at the 3’ splice 
site.  Another 0.76 per cent use the related GC-AG rule and 0.1 per cent of the genes 
follow the rare AT-AC rule18. The remaining 1.14 per cent would include mostly 
sequencing errors.  There appears to be a larger frequency of alternative splicing in the 
human genome compared to the worm and fly genome.  As already mentioned, this 
could be an important explanation for the presence of fewer genes in the genome than 
was expected. 
The knowledge of the human proteome can be determined from the draft sequence 
based on homologues/analogues from completely sequenced eukaryotic genomes such as 
the yeast and partially sequenced genomes of the mouse, wheat etc.  Such comparisons 
also yield useful insights into the commonalties and differences between these 
organisms.  Specific information regarding protein domains, domain families, horizontal 
transfer of genes, mechanism(s) of alternative splicing and post-translational 
modifications can be elicited.  Compared to the worm and the fly proteome (both are 
invertebrates), the human proteome has a higher proportion of genes falling in the 
category of the immune system, cytoskeleton, transcription and translation18. Humans 
also have more proteins that fall in the multifunctional category (i.e., proteins with 
multiple functions) than the other two species.  The human genome contains several 
genes (223 to be exact) that do not have homology with invertebrate proteins but 
resemble bacterial protein18. To rule out the possibility of bacterial contamination, 
primers based on these sequences were used to perform PCR on freshly isolated human 
genomic DNA, and successful amplification confirmed them to be genuine human 
genes18. Several of these proteins however share significant homology with proteins 
from other vertebrate species.  There could be two possible explanations for this 
phenomenon; (i) these genes were present in the primordial ancestor and were lost only 
in the invertebrate lineage or (ii) these genes in the vertebrate species (including 
humans), are a result of horizontal transfer from bacteria.  Such horizontal transfers were 
selected in the vertebrates because they provided some selective advantage.  For 
example, the mitochondrial outer membrane enzyme gene monoamine oxidase, which is 
a target for same drugs, used in psychiatric disorders, probably, is a result of horizontal 
transfer from bacteria.  A recent report has however challenged the hypothesis of 
horizontal transfer to explain this phenomenon26. 
The comparison of the human proteome with that of the worm, the fly and the yeast 
has revealed several orthologous groups between the three. Orthologues are equivalent 
genes in different species that might have evolved from a common ancestor. Most of the 
orthologues identified by the human genome project initiative belong to the class of 
housekeeping proteins that function mainly in metabolism, DNA replication, DNA 
repair, and translation.  Several of the orthologues can be clustered into families.  The 
number of members per family may differ in various species, although they exhibit 
significant homology.  The orthologues between human and fly and human and worm 
mainly include enzymes known to be conserved through evolution, including enzymes 
involved in DNA/RNA processing.  Other categories include transferases, 
oxidoreductases, ligases, lyases, isomerases, proteases, molecular chaperons, and 
GTPases.  The protein families that differ significantly from other genomes include those 
involved in acquired immune function; neural development; inter and intra cellular 
signaling pathways in homeostasis; and apoptosis.  One can appreciate the fact that each 
of these categories are specific to vertebrates.  Clustering of protein sets for each 
organism has led to the identification of paralogous genes for each species.  Paralogues 
are homologous sequences (sequences that share a common evolutionary ancestor) that 
diverged by gene duplication (within one organism).  The paralogues could differ by 
having an increased or reduced number of exons, with or without introns.  The study of 
orthologues and paralogues has also resulted in identification of several vertebrate-
specific protein families.  However, the total fraction of vertebrate-specific protein 
families identified was only 7 per cent18. This means that very few protein domains have 
originated in the vertebrate lineage with most domains having originated in a common 
animal ancestor.  As expected, only one of the vertebrate-specific protein families 
represents enzymes, validating the theory of ancient origin of most enzymes18. 
Venter and colleagues have tried to classify genes based on their molecular function.  
Out of the total genes that they could predict, 41.7 per cent could not be assigned any 
function25. About 10 per cent of genes were predicted to have an enzymatic function, 
about 12 per cent were classified as signal transducers and another 12-13 per cent as 
nucleic acid binding proteins or nucleic acid enzymes.  Venter’s group have also 
identified several paralogous genes.  According to their analyses, majority of intronless 
paralogues belong to the class of genes involved in the translational process and nuclear 
regulation as well as metabolic enzymes25. The study of pseudogenes, that arise through 
such retrotransposition events, or segmental duplications, highlights the evolutionary 
forces that may result in gene inactivations25. 
The identification of vertebrate-specific gene families has also highlighted important 
physiological differences between vertebrates and invertebrates.  Most of the vertebrate-
specific gene families cater to functions such as immunity, nervous system etc.  
Although there appear to be very few novel protein domains that have been discovered in 
the human genome, there seems to be a far greater extent of innovation in terms of novel 
vertebrate proteins, which arise by re-shuffling of domains (as they are arranged on a 
polypeptide chain). The human genome has generated 1.8 times, more novel architecture 
(from the same existing protein domains) as compared to the worm and the fly, and 5.8 
times more than the yeast18. Most of this novel architecture is evident in extracellular and 
transmembrane proteins.  Another important feature of the vertebrate protein families is 
their expansion, as evident from the human genome. Gene duplication has led to the 
creation of new members in each family. The human genome contains several examples 
that bear out this fact. There are 30 fibroblast growth factors in humans as opposed to 
only two each in the fly and the worm18. There is a similar expansion in proteins 
belonging to the TGFb family, the intermediate filament proteins family, the olfactory 
receptor family and the immunoglobulin family.  Each one of these families are 
hallmarks of important physiological processes in vertebrates.  Therefore, the complexity 
of the human proteome stems not from a moderately greater number of genes but from a 
greater innovation in terms of generation of a novel architecture from existing domains, 
larger protein/domain families and multidomain families.  As already stated, other 
factors like alternative splicing, post-translational modifications along with the ones 
mentioned previously, together lead to the complexity of the human proteome.  Some 
other mechanisms that may lead to a larger protein diversity include RNA editing27 and 
various forms of translational regulations (like the use of internal ribosome entry sites)28. 
A comparative genomics study has revealed that the fly has 177 of the 289 human 
disease genes examined29. 
In bacteria, genes present in close proximity often encode proteins that function in a 
common pathway.  This is not true for higher organisms.  However, conservation of gene 
location between two diverse organisms suggests their common origin and helps in the 
identification of disease loci.  The presence of linked genes in diverse organisms such as 
the humans, mice, worm and the fly has been studied18. ‘Conserved synteny’ has been 
used to describe the presence of at least two genes that reside in the same chromosome in 
different species.  About 180 such chromosomal segments, where the linear order of 
gene loci has been conserved in human and mice, based on search for orthologous genes, 
has been discovered.  The segments ranged from about 15 to 90 Mb18. 
The genome structure includes several features apart from the coding region.  The 
draft genome sequence has enabled an estimation of the average GC content to be about 
41 per cent18. There are, as expected, regions (in some cases more than 10 Mb), with a 
GC content of 36 per cent18 and similarly some specific regions have a GC content of 47 
per cent.  One common feature associated with coding regions is the presence of CpG 
islands located at the 5' end of genes.  The methylation of such islands is found to be 
associated with imprinting and gene inactivation.  Computational methods to detect CpG 
islands have defined them as stretches of DNA more than 200 bp, having a G+C content 
of more than 50 per cent, with a high frequency of the CG dinucleotide, significantly 
higher than what can be predicted based on probability30,31. The CpG dinucleotide occurs 
at about one fifth of the 4 per cent frequency which is expected based on probability.  
The study by Venter and colleagues have confirmed the belief that the CpG islands are 
usually concentrated close to the first exon of genes25. The CpG dinucleotide is grossly 
misrepresented in the genome, which is expected since the cytosine in CpG is susceptible 
to methylation followed by deamination, which leads to mutation of Cytosine to 
Thymine, the most common form of SNP found in the human genome.  A search for 
CpG islands has identified 28,890 such islands, excluding those that are present in 
repeat-rich regions18. Most of these islands are short, less than 850 bp, and these smaller 
islands are consistent with the gene regulatory function proposed for them.  The density 
of these islands varies with different chromosomes but correlates with gene density per 
chromosome.  In other words, chromosomes with a higher gene density have a high 
density of CpG islands18. 
The human genome also gives an opportunity to collate the previously determined 
genetic and physical map of each chromosome.  Such an analysis has revealed that the 
recombination rates (crossing over frequency) are higher near telomeres (ends of the 
chromosomes) and lower near centromeres (center of the chromosomes)18. Moreover, 
long chromosome arms have a comparatively low recombination rate compared to short 
chromosome arms.  This also holds true for yeast chromosomes.  There could be several 
explanations for this inverse relationship.  In terms of probability, the chance of 
recombination increases with increase in length of the chromosome arm.  Therefore, a 
higher recombination rate for shorter arms could be a compensatory mechanism for the 
lower probability of recombination.  Another explanation could be the presence of a 
surveillance mechanism of pos itive crossover interference that inhibits additional 
crossovers in regions neighboring a crossover event.  Differences in overall 
recombination rate have been observed between various chromosomes as well as 
between identical chromosomes from the two sexes18. Further analysis is required to 
determine the mechanism(s) of the observed differential recombination frequencies. 
Several organisms that are taxonomically related or have similar gene content, differ 
greatly in their genome size.  This anamoly has been termed as the ‘C-value paradox’.  
The anamoly is due to the presence of large chunks of repetitive DNA in large genomes.  
About 25 per cent of nuclear DNA is composed of genes and related sequences out of 
which 1-2 per cent are actual coding regions (exons) and the rest include non-coding 
regions (introns, 5’ and 3’ UTRs etc.). The remaining 75 per cent includes highly 
repetitive DNA (40%) and unique or moderately repetitive DNA (35%)18. Repeat regions 
can be of various types and generally include (i) pseudogenes, (ii) repeat regions present 
near the centromere and the telomere, (iii) simple sequence repeats (SSRs) consisting of 
mono/di/tri nucleotide repeats such as (A) n or (CA) n or (CAG)n, 
(iv) transposon-derived repeats and, (v) segmental duplications, arising due to chunks of 
DNA copied from one region of the genome into another.  The repeat regions are 
actually rich sources of information to understand the process of evolution, mutation and 
selection.  They are important tools for studying population genetics and medical 
genetics and serve as molecular markers to map chromosomal regions.  In medical 
genetics, their role in mapping disease loci for genetic disorders is extremely important. 
Overall, the human genome is very stable, mutations occur at the rate of 10-9.  
However, the repeat regions are a major source of variation in the human genome, and 
among these the transposable elements are the most active and also represent a major 
proportion of the repeat regions. Moreover, the total number of transposons in the human 
genome appears to be higher compared to the other genomes that have been sequenced.  
The transposable elements in mammals belong to four major categories namely (i) long 
interspersed repeats (LINES), (ii) short interspersed repeats (SINEs),  (iii) LTR 
retrotransposons and, (iv) DNA transposons.  LINEs are full fledged transposons, which 
include genes for their propagation.  SINEs are shorter than LINEs, contain no ORFs and 
‘piggy back’ on LINEs for their propagation.  About 5000 full length non-LTR 
retrotransposons are present out of which about two may still be capable of 
retrotransposition18. Recently, two independent studies have shown that the LINE-1 (L1) 
retrotransposon, the most common retrotransposons in the human genome, can actually 
cause genome instability mainly through deletions in transformed cell32-33.  New Ll 
retrotranspositions are estimated to occur by creation of specific inversions by twin 
priming mechanism34. The LTR retrotransposons are flanked by long terminal direct 
repeats (LTR) and the retrotransposons themselves contain genes for protease, reverse 
transcriptase (pol), RnaseH and integrase.  The mechanism of retrotransposition is akin 
to that of common retroviruses.  It is possible that retroviruses arose from such 
transposons by the acquisition of an envelope (env) gene.  Most of the LTR 
retrotransposons in the genome are present as fossils, since they have only the LTR, and 
have lost the transposon element due to recombination between two LTRs.  The DNA 
transposons resemble typical bacterial transposons, they have terminal inverted repeats 
which enclose the transposase gene.  The transposase gene product binds at the terminal 
repeats for propagation through a ‘cut and paste’ mechanism (whereas L1 will move 
through a ‘copy and paste’ mechanism).  All transposons have different means to ensure 
their propagation.  LINEs and SINEs depend on vertical transfer, whereas DNA 
transposons depend mainly on horizontal propagation.  Since LINEs and SINEs require 
processing in the nucleus and their encoded protein product binds to their own RNA, 
they are sustained for a longer time in the genome18. However, the DNA transposons do 
not have any such mechanism and therefore, have a shorter life span in any given 
genome. 
Interesting differences between repeat sequences of human and other genomes have 
been revealed18. Firstly, the euchromatin region of the human genome has a higher 
density of repeat elements compared to other genomes such as that of the fly, the worm 
and the mustard weed.  Secondly, the transposons in the human genome are more ancient 
than the ones in the other genomes.  Thirdly, the other genomes do not have any 
dominant families like the LINEs in the human genome18. Moreover, unlike the human 
genome, the genomes of Drosophila and C. elegans have a high frequency of short-lived 
DNA transposons.  These features, relating to repeat regions, of the human genome are 
probably a conserved feature of all mammals.  As expected, the density of repeat regions 
varies in different regions of the genome18. Some regions of the genome are repeat-rich 
whereas the others are devoid of repeats.  The Y chromosomes appears to be younger 
than the other chromosomes, based on the age of the repeat elements present. 
The human genome also characteristically contains several simple sequence repeats 
(SSRs).  SSRs are called microsatellites if the repeating unit number is less than three 
and minisatellites if it is four or more.  Trinucleotide repeats are more rare than the 
dinucleotide repeats.  The SSRs are important in the context of mapping of disease loci.  
Several disease loci have been mapped by using such repeats since they exhibit a great 
degree of length polymorphism, probably due to slippage during DNA replication.  
Therefore, a comprehensive cataloguing of such repeats is important in the context of 
study of novel genetic disorders. 
Segmental duplication occurs when a large chunk of the genome (1-200 kb) is 
duplicated in another region, in the same chromosome (intrachromosomal duplication) or 
in a different non-homologous chromosome (interchromosomal duplication).  Most of 
such duplications in the human genome have a high degree of sequence identity thereby 
indicating a more recent origin.  The analyses of chromosome 21 and 22 indicate that a 
high proportion of duplicated regions are located close to the centromere.  The region 
neighboring the telomeres also appears to be rich in duplicated regions.  There may exist 
a mechanism to safeguard against frequent duplications from occurring in other regions 
of the chromosomes.  A recent study by Bailey and coworkers35 revealed several recent 
segmental duplications in the human genome, some of which have also been associated 
with genetic disorders.  As seen for retrotranspositions, segmental duplications also 
could be one mechanism, which would increase the protein repertoire in the human cell. 
 Significance of human genome sequence 
Mapping disease loci 
The preferred mode of mapping disease genes used to be through positional cloning36. 
This requires study of genetic markers that are linked to the disease phenotype in 
affected members in a family, followed by identification of genes present in and around 
the marker that is linked to the disease (about 1 Mb on both sides of the marker).  The 
availability of the draft sequence has increased the number of polymorphic markers 
available to facilitate gene mapping studies.  These include microsatellite as well as SNP 
markers.  More importantly, the genome sequence has also facilitated direct in silico 
(within the computer) gene identification.  Several disease genes (about 30) have already 
been cloned based on the human genome draft sequence37-40. The availability of the 
genome sequence has also helped in the identification of paralogues of disease genes, 
which are useful in determining the etiology of related genetic disorders.  For example, 
Presenilin-1 and Presenilin-2; mutations in either of these paralogous genes can cause 
early onset Alzheimer’s disease41,42. The paralogues can also be useful for designing 
potential therapics. The Human genome draft sequence is also proving to be useful to 
determine the genetic basis for chromosomal deletions occurring due to unequal crossing 
over between intrachromosomal duplications, for example, the  iGeorge/velocardiofacial 
syndrome region on chromosome 2243 and the William’s-Beuren syndrome recurrent 
deletion on chromosome 744. The human genome sequence has also resulted in revealing 
disease loci associated with a class of neurodegenerative diseases known as transmissible 
spongiform encephalopathies (TSEs) which were earlier shown to be intimately linked 
with the prion proteins.  Recently, by using a combination of bioinformatics and 
molecular approaches, three genes within a 55 kb interval were identified in the human 
prion protein locus viz.,  PRNP, DOPPEL or PRND and PRNT45. This locus has been 
implicated in human prion disorders.  A 9 cM genome screen on 437 Alzheimer’s 
disease families has revealed 12 additional disease loci on different chromosomes, thus 
paving the way for a quick identification of genes that may play a major role in the 
progression of this important disorder46. 
Drug targets 
For the past several decades, the pharmaceutical industry has depended upon a limited 
set of drug targets; a recent compendium has listed only 483 drug targets which account 
for almost all drugs on the market47,48. The draft human genome sequence has however 
resulted in a ‘gold rush’ for big pharmaceutical companies, the race to identify new drug 
targets through high throughput genomic research.  Careful analysis of the human 
genome draft sequence is already beginning to reveal several new drug targets (Table I). 
A putative homologue of the serotonin receptor has been identified from the long arm of 
chromosome 1149. The gene, named 5-HT3B, and its product resembles with the 
previously identified receptor 5-HT3A.  Given the central role of the serotonin pathway 
in mood disorders and schizophrenia, the discovery of a major new therapeutic target is 
of considerable importance.  Simila rly a second receptor for the slow reacting substance 
of anaphylaxis (named CysLT2), has been identified using the combination of a rat EST 
and the human genome sequence50. As the leukotriene pathway has been a significant 
target for the development of drugs against asthma, the discovery of this new receptor 
has important consequences.  b-amyloid, whose deposition in senile plaques is the 
hallmark of Alzheimer’s disease, is generated by proteolytic processing of the amyloid 
precursor protein (APP).  One of the enzymes involved is the b-site APP-cleaving 
enzyme (beta secretase, BACE), which is a transmembrane aspartyl protease.  A second 
enzyme named BACE2 has been identified, based on a computational search of the 
public human draft genome sequence51. The development of antagonists to BACE and 
BACE2 represents a promising approach to preventing Alzheimer’s disease.  Similar 
searches have yielded several paralogues including putative dopamine receptors, 
purinergic receptors, insulin-like growth factor receptors etc18. Many of these could 
prove to be useful to identify several such paralogues. 
Basic research 
The draft sequence is expected to provide answers to several unsolved basic questions 
including those relating to complex phenomenon such as embryonic development, brain 
function etc.  The human genome is touted as the master plan for building an organism.  
But we are still a long way away from understanding how that “master plan” directs 
construction.  Traditionally, developmental geneticists have learned how genes control 
development by altering a gene and observing the phenotype, in model organisms such 
as the fruit fly Drosophila melanogaster, the nematode worm, and the mouse.  Complete 
genomes (the fly, worm, and human) have simplified the process of locating genes that 
cause intriguing abnormalities.  One unsolved mystery, concerning the polymorphic 
bitter taste was actually solved based on the draft sequence.  The gene was mapped to a 
specific region where a G-protein coupled receptor was located.  The receptor is 
expressed exclusively in the taste buds and its expression can be regulated in response to 
bitter substances in cell culture52-55. The Taslr3 gene, which encodes a novel taste 
receptor, was also identified from the draft sequence and is allelic to the sweet 
responsiveness locus Sac of the mouse56. 
Single Nucleotide Polymorphisms (SNPs) and the birth of predictive medicine  
The majority of human DNA polymorphisms are single nucleotide polymorphisms 
(SNPs), which are single base pair positions in genomic DNA at which different 
sequence alternatives (alleles) exist in normal individuals in some population(s).  They 
are distinguished from rare sequence variations by a requirement for the least abundant 
allele to have a frequency of more than 1 per cent in the population.  The density of 
SNPs differ between different genomic regions, but the overall frequency is estimated to 
be around 1 in 200-600 base pairs, resulting in several million potential single base 
differences between any two individuals.  According to recent studies, there is an 
estimated 1.4 to 3.1 million SNPs in the human57,58.  An important fallout of the HGP is 
the generation of an SNP map of the human genome.  The increased prevalence of SNPs 
in the human genome compared to other types of sequence variations (such as 
microsatellites) make them ideal for genotyping and genetic dissection of complex traits 
and disease.  SNPs can occur in both coding (gene) and noncoding regions.  SNPs have 
an average spacing of 1.9 kb and 63 per cent of 5 kb intervals contain an SNP58. This 
high prevalence of SNPs within the human genome allows the usage of SNPs as ideal 
candidate markers.  In general, higher the frequency of an SNP allele, older the mutation 
that produced it; so high-frequency SNPs largely predate human population 
diversification, and this information can be used in human evolution studies.  Most SNPs 
have no effect on cell function but SNPs that occur in coding regions may underlie 
differences in our susceptibility to, or protection from, various diseases; in the age of 
onset and severity of illness; and in the way our bodies respond to treatment58. 
The frequency of occurrence of SNPs in individual autosomes lies in the range of 5.19 
to 8.79 differences per 10 kb.  The variation in X chromosomes is about 4.69 difference 
per 10 kb and 1.51 differences per 10 kb lie in the Y chromosome non-recombining 
region57. The lower frequency in the X chromosome compared to antosomes can be 
easily explained based on the fact that the effective population size for the X 
chromosome is 3/4th of the autosomes.  Similarly, the effective size for the Y 
chromosomes is 20 per cent that of autosomes57. Even within a single chromosome, the 
nucleotide diversity is not uniformly distributed18. That is not surprising since the 
mutation rate does not display a uniform distribution along the sequence.  Some genomic 
regions have significantly lower or higher diversity than the average.  For example, the 
HLA locus in chromosome 6, which encodes proteins that present antigens to the 
immune system, shows very high heterozygosity, which reaches more than 30 SNPs per 
10 kb.  Presence of a higher GC content correlates with a higher nucleotide diversity, 
which reflects, at least in part, the high frequency of CpG to TpG mutations arising from 
the deamination of methylated 5-methylcytosine57. Some of the significant uses of SNPs 
are discussed below: 
Mapping of disease genes 
The prevalence of SNPs makes them extremely useful for disease associated studies.  
In several cases, an SNP can be directly linked to a disease.  Several diseases are directly 
caused due to single nucleotide changes such as thalassaemia, muscular dystrophy, 
phenylketonuria, long QT syndrome, familial hypertrophic cardiomyopathy etc.  A 
recent study has led to the identification of novel mutations that cause primary congenital 
glaucoma (PCG) in Indian pedigrees59. This study has also resulted in the development 
of simple PCR-REA based detection systems for a quick and simple diagnosis of PCG59. 
A similar approach was adopted for other genetic disorders of the eye such as the 
Axenfeld-Rieger anomaly60 and retinoblastoma61. It is important to determine the disease 
causing SNPs for common genetic disorders in our population and create a knowledge-
based database for the same.  This will facilitate the establishment of an effective 
molecular screening regime for specific genetic disorders based on the common SNPs. 
The identification of SNPs can also be used to measure linkage disequilibrium within the 
human genome62. Linkage disequilibrium is a measure of the extent to which genomic 
sequences representing specific allelic combinations (haplotypes) from a common 
ancestor have persisted over the course of evolution62. Study of linkage disequilibrium 
through SNPs can be used to map disease related genetic loci as well as to answer 
questions on evolution of human populations57,63. 
Finding genetic loci associated with a disease phenotype is not an easy proposition.  
This is especially true in the case of complex diseases or traits which result from the 
cumulative influences of multiple susceptibility factors, some genetic, some 
environmental.  Identifying the level of contribution of each individual disease 
susceptibility locus/factor toward the disease phenotype is a challenging endeavour.  
Though positional cloning has been employed successfully to identify genetic loci 
associated with diseases that follow a simple Mendelian pattern of inheritance64, genetic 
mapping displays limited success in defining multiple loci responsible for complex traits, 
especially loci that have minor contributions to the phenotype65. Whereas previous 
efforts at identifying trait associated genetic loci involved considerable effort to discover 
polymorphisms across the region of interest, the high prevalence of SNPs significantly 
facilitates the search for target loci66. The main use of the human SNP map will be to 
dissect the contributions of individual genes to diseases that have a complex, multigene 
basis, such as central nervous system disorders, cancer and cardiovascular disease67. 
Some advances have already been made in this area.  SNPs have recently been 
implicated in risks for Alzheimer68. Martin and co-workers69 used five SNPs within the 
tau gene to show a strong linkage between this gene and idiopathic Parkinson disease. 
Pharmacogenomics 
One of the major complications facing drug therapy is the individual variations among 
patient populations with respect to their responses to drug treatment.  Not only do 
medications vary in their efficacy among individual patients, a drug that is tested and 
found to be safe in one individual might prove lethal for another.  These individual 
phenotypic differences can be directly attributed to polymorphisms in genes that encode 
key protein(s) molecules that affect the impact of the drug. Individual genetic variations 
affect several functional aspects of a drug including drug absorption, distribution, 
metabolism, excretion and drug target specificity70. Understanding the nature of these 
polymorphisms would allow physicians to customize the selected medication so as to 
meet the specific treatment requirements of individual patients (pharmacogenomics).   
 Since SNPs are the most prevalent type of polymorphism within the human genome, 
individual SNPs could be identified that correlate with the individual variations in drug 
response71. Availability of the entire human genome sequence information as well as 
extensive knowledge of the SNPs that occur within the human genome, facilitates the 
process of associating genetic variations with inter-individual phenotypic differences.  
Pharmacogenomics, the concept of personalized and effective drug selection based on 
the genotype of a patient, enables the improvement of drug efficacy, safety, as well as 
the cost-effectiveness of the treatment71. 
Some typical examples of genes that play a role in drug response, identified through 
pharmacogenetic studies, are given in Table II. One example is the SNP determined in 
the Cyp2D6 locus, which affects metabolism of the pain alleviating drug codein.  This 
polymorphism limits the conversion of codeine to its active morphine form and 
therefore, patients harbouring this polymorphism do not get pain relief when they take 
the normal dose of codeine.  Another example is the presence of a gene variant on both 
chromosomes that codes for an enzyme thiopurine S-methyltransferase (TMPT), in 
approximately one in 200 Caucasians.  The TMPT metabolizes a class of drugs, 
thiopurines, used for the treatment of autoimmune diseases such as Crohn’s disease and 
rheumatoid arthritis, renal transplant patients, lymphoblastic leukemia and childhood 
leukemias.  Individuals with this SNP are unable to metabolize the drug leading to a 
toxic accumulation of the drug in the bloodstream.  Members of the CYP3A family are 
the most abundant CYPs in the human liver and intestine.  Their substrates include 
cyclosporin A, HIV protease inhibitors, calcium channel blockers, and some anti-cancer 
drugs.  The variations in the levels of CYP3A, sometimes upto a 30 fold difference, has 
been observed for a long time in different populations.  Genetic polymorphisms were 
recently identified in the promoter of several members of this family of genes, which was 
shown to be responsible for the polymorphic levels in a recent study72. This study has 
also revealed the role of specific SNPs in the coding region of CYP3A5 that lead to 
alternative splicing and truncation of the protein and thereby leading to the drastic 
reduction in protein levels. 
The cytochrome P 450 enzymes play a major role in the metabolism of drugs.  The 
SNP in the CYP2D6 gene is very common in some populations.  CYP2D6 is involved in 
the metabolism of about 30-40 drugs and SNPs that result in poor metabolism as well as 
rapid metabolism have been identified.  Similarly CYP2C19 is another gene in which 
SNPs result in generation of a truncated protein with little or no activity.  Sometimes an 
SNP may even be lethal, The drug warfarin is lethal when given as an overdose, as it 
may cause excessive bleeding.  An SNP in the CYP2C9  protein, which metabolises this 
drug, leads to a very low rate of metabolism.  If a person harbouring this polymorphism 
is given a normal dose of warfarin, then it may turn out to be lethal.  Therefore, genetic 
testing before prescribing the drug is very important in such cases.  This is an example of 
the significant effect that pharmacogenomics will have on the future of medical 
treatment and the way pharmaceuticals are prescribed for each individual.  With the 
advent of lineage independent genotyping through SNP analysis, pharmaceutical 
companies hope to be able to utilize this new method to develop drugs in a more targeted 
fashion and to significantly narrow down the number of test subjects by conducting 
genotyping tests. 
Table I. New drug targets 
New target gene Homologue Role 
——————————————————————————————————————————— 
5-HT3A (Serotonin receptor) 5-HT3A Schizophrenia 
Second receptor for Cysteinyl CysLT1 Allergic  
leukotrienes (CysLT2)  disorders  
BACE2 BACE1 Alzheimer’s 
——————————————————————————————————————— 
 Table II. Genes that modulate drug response as a function of SNPs present in them  
——————————————————————————————————————— 
Locus          Drugs    Role  
——————————————————————————————————————— 
Drug metabolism 
CYP2D6 Codein, Fluoxetine, Antidepressants, pain 
 Propafenone, killers 
CYP2C9 Warfarin Anti-coagulant 
CYP2C19 Omeprazole  Proton pump inhibitor 
Thiopurine S-methyltransferase 6-Mercaptopurine, Anti cancer, 
 azathioprine  immunosuppressor 
Dihydropyrimidine dehydrogenase 5-Fluorouracil Inhibits cell division (anti 
  cancer) 
 
N-acetyltransferase 2 Isoniazid, Hydralazine  Inhibits synthesis of 
   bacterial mycolic acid 
   (anti mycobacterial), 
   Relaxes vascular smooth 
   muscles (used to lower 
   blood pressure) 
UDP-glucuronosyltransferase lAl Irinotecan  Inhibits topoisomerase II 
   (anti cancer) 
Drug transport 
MDR1 Digoxin, Fexofenadine Blocks sodium potassium 
  ion exchange pump (for 
  heart failure), anti 
  histamine (for allergy) 
Drug targets 
ACE Enalapril Angiotensin converting 
  enzyme inhibitor (for 
  hypertension) 
b2-adrenergic receptor Albuterol, Terbutaline Bronchodilator (for 
  asthma) 
ALOX5 ABT-761 Lipoxygenase inhibitor 
   (anti cancer) 
5-HT2A, 5-HT6 Clozapine (For  schizophrenia) 
 
Disease pathology 
ApoE4 Tacrine For Alzheimer disease 
 
Stromelysin- 1 Pravastatins For Alzheimer disease 
 
HERG, KvLQT1, Mink, Terfenadine, anti- Antihistamine, anti- 
MiRP1 arrhythmics arrhythmic  
 
SNPs, single nucleotide polymorphisms  
————————————————————————————————————————  
 
 
 
 
 The future  
Since both the sequencing efforts have resulted in only a draft sequence, it needs to be 
updated and the gaps need to be filled to result in the complete sequence of the human 
genome.  This will firstly involve complete coverage of the euchromatic region through 
sequencing of additional clones.  The next stage would involve the screening of 
additional clones in order to close gaps present in the contigs.  This will be followed by 
additional sequencing of heterochromatic regions and repeat-rich regions , although it 
may prove to be difficult using existing sequencing technologies.  Efforts are already 
underway to identify those segments that are missing in the working draft sequence of 
the human genome, by constructing a high resolution radiation hybrid map of the human 
genome draft sequence73. The other important endeavour will be to complete the list of 
proteins encoded by the human genome, that direct our development, appearance, 
behaviour, talents, and susceptibility to disease18,25. The interpretation of the human 
genome organization will also depend, to a large extent, on genomes of other organisms, 
which will facilitate the understanding of the functioning, regulation, and origins of our 
own genes29,74,75. The importance of the comparative efforts has already been validated 
in the fields of anatomy, physiology, and medicine.  Decisions and priorities regarding 
the choice of organisms for whole genome sequencing will ultimately shape biology and 
influence the potential applications of the completed genome sequence.  The other 
important step will be to generate a complete collection of human cDNAs76.  This would 
be followed by cataloguing all possible gene specific alternative splicing patterns. 
Completion of the Human Genome Project has enabled researchers to analyze 
sequence variation types, patterns and their relative frequencies within the human 
genome.  Studying the genetic variation with relation to the human genome allows us to 
determine the evolutionary history of man and to map the evolutionary relationship 
shared by the human genome with the genomes of other organisms.  But more 
importantly, this has brought about a change from the previously dominating focus on 
gene discovery to one aimed at understanding gene function.  The emerging transcript 
profiling techniques are powerful tools that represent a new approach to the elucidation 
of gene function and the investigation of differences at the level of gene regulation, and 
can identify genes not previously implicated/known to be involved in a particular 
biological and/or pathological process.  A related development will be the study of 
regulatory regions within the genome.  These regions are important as their action results 
in differences between the various cell types.  Regulatory regions of most genes remain 
uncharacterized.  Comparative genomics has already resulted in characterization of some 
of these sequences by comparison of orthologous genes77. A study of various epigenetic 
mechanisms such as DNA methylation is another important problem, which should be 
addressed immediately.  In this context, a Human Epigenome Project has been recently 
launched78,79. 
The development of new genomics and proteomics techniques is enabling researchers 
to analyze whole genome profile of cells and tissues, instead of investigating one gene at 
a time.  Kim and coworkers80 have analyzed the relative activity of nearly every worm 
gene at different developmental stages through several microarray based experiments. 
Similar work on human genes is following. The important areas that will be benefited by 
the whole genome approach include embryonic development, differentiation, brain 
function, stem cell biology etc.  It is now possible to analyze which genes are switched 
on in human embryonic stem cells that can develop into any cell type. Following the 
pattern of gene activity in undifferentiated cells during the development into certain 
tissue types, could throw light on the molecular features of a specific stem cell. 
The brain is the most complex organ in the body and as already mentioned, a large 
proportion of the total gene pool is thought to be involved in constructing, wiring up, and 
maintaining the nervous system.  Neuroscientists are now working to decipher the 
molecular genetic pathways that underlie brain function.  The completed genome will 
also accelerate the search for genes at fault in neurodegenerative diseases.  Psychiatrists 
hope to solve the intricacies of human behaviour based on the human genome sequence.  
For example, the recent work of Nestler and colleague81 has identified genes that may be 
linked to addiction to cocaine, based on differences in the dopamine transporters. 
Ethical issues 
It is the responsibility of all members of society to ensure that knowledge resulting 
from scientific research is used responsibly and judiciously.  Although, science is often 
regarded as being neutral, the application and products of research may not be.  The way 
in which we use this knowledge has various ethical implications that must be considered.  
The HGP has expectedly raised several ethical issues as a fallout of the unraveling of the 
human genome sequence, pertaining to diagnostics, health care, insurance etc. 
The National Human Genome Research Institute’s (NHGRI) Ethical, Legal and Social 
Implications (ELSI) Programme was established in 1990 as an integral part of the 
Human Genome Project.  The planners of the Human Genome Project recognized that 
the information gained from mapping and sequencing the human genome would have 
profound implications for individuals, families and society.  While this information 
would have the potential to dramatically improve human health, they also realized that it 
would raise a number of complex ethical, legal and social issues.  How should this new 
genetic information be interpreted and used?  Who should have access to it?  How can 
people be protected from the harm that might result from its improper disclosure or use?  
The ELSI research programme was established to address these issues and has become 
an integral part of the HGP.  ELSI provides a new approach to scientific research by 
identifying, analyzing and addressing the ethical, legal and social implications of human 
genetics research at the same time that the basic science is being studied.  In this way, 
problem areas can be identified and solutions developed before scientific information is 
integrated into health care practice.  In January, 1990, the ELSI Working Group issued 
its first report and defined the function and purpose of the ELSI programme as follows: 
(i) To anticipate and address the implications for individuals and society of mapping and 
sequencing the human genome; (ii) to examine the ethical, legal and social consequences 
of mapping and sequencing the human genome; (iii) to stimulate public discussion of the 
issues; and (iv) to develop policy options that would assure that the information be used 
to benefit individuals and society. 
Several ethical issues were raised right from the beginning of the HGP. One of the 
initial concerns was whether it was worthwhile to invest so much money to unravel the 
whole genome, the majority of which consisted of non-coding DNA.  However, this 
issue was solved since scientists argued successfully in favour of complete sequencing 
given the importance of physical and genetic maps, which would be made available after 
complete sequencing.  Another concern was regarding the discovery of a gene, which 
might result in a possible genetic disorder, much before the disorder manifests itself.  
This might result in panic, anxiety and frustration among the general public.  However, 
on the other side, the development of efficient diagnostic methods will make the 
prognosis and management of the condition easier.  It is important that policy makers do 
not put major blocks in using the human genome sequence data for research purposes. 
A survey conducted in 37 countries in 1997, has revealed that invasion of privacy, as a 
fallout of the HGP, is the most serious concern of professionals.  They also agreed that 
neither employers nor insurance companies should have access to a person’s genetic 
information without his or her consent.  It is also important to protect ‘medical’ 
information rather than only ‘genetic’ information.  However, certain types of medical 
information, that includes epidemiology and studies on allele frequency, disease 
prevalence etc ., should be freely available to researchers.  Privacy concern for such 
public health issues is inherently reduced since the data always pertain to a population 
and not to an individual. 
Conclusions: The Book of Life is poised to change the future of medicine  
There are several paradigm shifts taking place in the field of biomedical research as a 
fallout of the human genome sequencing.  The goal of the Human Genome Project is to 
provide scientists with powerful new tools to help them clear the research hurdles that 
keep them from understanding the molecular essence of several tragic and devastating 
illnesses, such as diabetes, cardiovascular diseases, immune system disorders, birth 
defects, schizophrenia, alcoholism, Alzheimer’s disease, and manic depression.  
Functional genomics studies are poised to make two major contributions to the 
development of more efficient drug therapy.  Firstly, functional genomic approaches will 
aid in the identification of the most suitable targets for drug intervention.  As already 
mentioned the current drug therapy rests on only about 500 odd targets, the emerging 
number is estimated to be in the range of 5,000 to 10,000 target molecules.  Secondly, 
pharmacogenomics will help in determining why patients respond differently to drugs.  
The genetic patterns that define these responses are being identified and used to target 
drugs more effectively during their development.  This approach will also allow for 
individualized drug therapy. 
The future of medicine is poised to undergo a sea change leading to an improved 
diagnostics for diseases, earlier detection of genetic predisposition to diseases, gene 
therapy and pharmacogenomics for custom drugs.  Given the rapid advances in the field 
of gene therapy, it might become possible to treat genetic disorders by correcting the 
errors in the gene itself, by replacing the faulty gene with a normal one or by switching 
off expression of the gene itself.  Another important area(s) that will be influenced is 
anthropology, evolution and human migration.  The elucidation of the human genome 
sequence is already facilitating the study of evolution through germline mutations in 
lineages, the study of migration of different populations, and comparison of breakpoints 
in the evolution with ages of populations and historical events.  The human genome 
project will help in understanding the choreography of the intimate dance of gene 
activity that begins after fertilization of the unicellular egg, culminating in the adult 
human being made of 1014 cells of various types and functions. 
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